

Peer M. Schatz

Further information on the Supervisory Board candidate nominated for election (Agenda Item 8)



Peer M. Schatz

Managing Director of PS Capital Management GmbH, Düsseldorf, Germany

Date/

place of birth: August 3, 1965 in New York, USA

Nationality: Austria/Switzerland

Education

- | | |
|------|--|
| 1989 | Master of Economics and Social Sciences, University of St. Gallen, Switzerland |
| 1991 | Master of Business Administration (MBA), University of Chicago Booth School of Business, USA |

Professional career and material activities

- | | |
|-------------|--|
| since 2019 | Managing Director, PS Capital Management GmbH, Düsseldorf, Germany |
| since 2019 | Special Advisor for the Supervisory Board QIAGEN N.V., Venlo, The Netherlands; until June 2021 |
| 2004 - 2019 | Chief Executive Officer, QIAGEN N.V., Venlo, The Netherlands |
| 1993 - 2004 | Chief Financial Officer, QIAGEN N.V., Venlo, The Netherlands |
| | Prior to that, various functions at Sandoz AG, ComputerLand AG, HTCS AG, among others. |

Memberships in other statutory supervisory boards or comparable domestic and foreign controlling bodies

No memberships in other legally required German supervisory boards at the time notice is given of the annual shareholders' meeting.

Memberships in comparable German and foreign controlling bodies of commercial enterprises at the time notice is given of the annual shareholders' meeting:

- Chairman of the Supervisory Board, Centogene N.V., Amsterdam, The Netherlands
- Chairman of the Board, Resolve BioSciences GmbH, Monheim am Rhein, Germany

Knowledge, skills and professional experience

Mr. Peer M. Schatz is an entrepreneur and executive with over 30 years of experience in the life sciences. Prior to 2019 Mr. Peer M. Schatz was Chief Executive Officer of QIAGEN N.V. Mr. Peer M. Schatz joined QIAGEN in 1993, when the company had under 30 employees and revenues of approximately US\$2 million. Under his direction, QIAGEN grew to employ more than 5,200 people in over 35 locations around the world and to record annual revenues of over US\$1.6 billion – with strong leadership positions in molecular diagnostics/precision medicine, research tools and advanced bioinformatics. He led more than 40 acquisitions for QIAGEN as well as QIAGEN's listing on NASDAQ (in 1996, making QIAGEN the first German company to do so) and the listings on the NYSE (2018) and the Frankfurt Stock Exchange (1997). Between 2009 and 2019 Mr. Peer M. Schatz held director positions for AdvaMedDx (in-vitro diagnostics industry organization of the USA) and ALDA (Analytical, Life Science & Diagnostics Association, USA). Mr. Peer M. Schatz participated in the founding and growth of a number of companies in the life sciences, primarily in biotechnology/biopharmaceuticals. Between 2001 and 2009, he was a partner in a venture capital firm focused on investments in the life sciences.

Siemens Healthineers AG

Henkestr. 127

91052 Erlangen, Germany

Tel.: +49 9131 84-0

siemens-healthineers.com